The use of hematopoietic stem cell transplantation or blood and marrow transplantation (BMT) is on the increase worldwide. With BMT's increasing utilization and increasing success, the number of BMT survivors in the United States alone is expected to surpass 500 000 by the year 2030. BMT survivors are susceptible to a host of long-term side effects and complications. The pediatric and adolescent and young adult (AYA) populations comprise an increasing proportion of BMT survivors. Though these populations are both at risk of a specific set of sequelae and faced with the additional challenge of transitioning to adult care, no previous literature has addressed their specific challenges. In this review, we illustrate with clinical vignettes the need for focused and specific survivorship clinics for pediatric/AYA BMT survivors. We then focus on the following areas pertaining to pediatric BMT survivorship and care: (1) psychological health, (2) neurocognition, (3) endocrine health, (4) infertility resources, (5) issues in transition from pediatric to adult clinicians, (6) preventative services and (7) cost of care issues.
INTRODUCTION
Hematopoietic stem cell transplantation, or blood and marrow transplantation (BMT), is increasingly used in the treatment of various malignant and nonmalignant diseases, both hematological and non-hematological in nature. 1 Of the predicted 500 000 BMT survivors in the United States by the year 2030, 14% will be survivors of childhood BMT (BMT at o 18 years of age). 2 The definition of a BMT survivor is an individual who has undergone a BMT, which begins on the day of stem cell infusion. BMT survivors are at risk of long-term side effects and complications due to their disease susceptibility, prior treatments and GVHD. Though many of the sequelae and their associated impacts on all age groups have been examined in a recent publication, 3 a literature gap is identified in the issues specific to pediatric and/or adolescent and young adult BMT survivors during and after their transition to adult care.
Both the prevalence and severity of chronic health conditions are greater in survivors of childhood BMT than they are in survivors of childhood cancer alone. 4 However, there is a paucity of data regarding pediatric and adolescent and young adult survivors of childhood BMT and their transition to adulthood. It is critical that attention is given to this subset of BMT survivors, for they bring with them a unique set of potential complications. Consider, as examples, Andrew and Asha, two survivors of childhood BMT who are now young adults.
Andrew is a 25-year-old white male who was diagnosed with a high-risk testicular tumor at the age of 15. He received a tandem autologous BMT following conditioning with carboplatin and etoposide. Though this process was curative, Andrew experienced many toxicities of such conditioning therapy, including interstitial pneumonia, hemorrhagic cystitis and chronic vomiting. 5 He now suffers from post-traumatic stress disorder (PTSD) and endocrine arrest of bone development, and is unemployed. Upon turning 18, Andrew lost his health insurance and remains uninsured, so he has not visited a physician in 7 years. He was recently diagnosed with AML.
Asha is a 25-year-old Asian-American female who works as a first-grade public school teacher. Her parents immigrated to the United States from Mumbai when she was an infant. At the age of five, she developed high-risk (Ph negative) B-cell ALL. Upon her first CR following induction chemotherapy, she was conditioned with TBI and cyclophosphamide and received an allogeneic BMT. When Asha turned 20, she was referred to an adult provider to continue with long-term follow-up. Asha and her husband had been unable to conceive, and she was diagnosed with premature ovarian failure. She has developed congestive heart failure and struggles with chronic GVHD. Asha and her husband blame the United States healthcare system for the decline in her health during the last 5 years of her life, which they believe could have been prevented.
Andrew and Asha may have little in common demographically, but they both exemplify some of the common late effects of childhood BMT. Appropriate monitoring of childhood BMT survivors allows for earlier detection of these events, decreasing morbidity. 6 Let us return to Asha. Because the chemotherapy she received prior to BMT consisted of a high cumulative dose of doxorubicin, she was put at high risk of anthracycline-associated cardiotoxicity, which can lead to a decline in left ventricular function. 7 Up to 65% of childhood survivors treated with anthracyclines demonstrate abnormalities in left ventricular contraction, which can progress to congestive heart failure. 8, 9 The Children's Oncology Group (COG) recommends baseline echocardiograms and electrocardiograms with QTc interval evaluations prior to anthracycline exposure and at certain milestones. 10 Asha also developed chronic GVHD, which occurs in~20% of childhood BMT survivors. 11 Asha's new adult healthcare provider discontinued her immunosuppressants when she was 21 years of age, causing her eventual relapse. Asha's inability to get pregnant due to premature ovarian failure is being attributed to her treatment. 11 High-dose cyclophosphamide can contribute to ovarian failure in females and azoospermia in males. 12, 13 Andrew experienced another type of endocrine dysfunctionarrest of the bones. BMT recipients are at increased risk for developing decreased bone mineral density and growth disorders after transplantation. 11, 14 Andrew also suffers from PTSD, which is an uncommon but well-recognized complication of BMT. Psychological stress reactions have been documented to occur in up to 80% of childhood BMT survivors. 15 Other psychological effects seen in this population include decline in social competence. 16 Andrew requires weekly meetings and pharmacological interventions for PTSD and is at an increased risk of suicide. 17 Though declared, 'cured' at 2 years post BMT, he now suffers from a much more aggressive and highly fatal cancer-secondary AML. BMT survivors are at a significantly higher risk of malignancy than the general population, 18 and secondary AML often develops following exposure to cytotoxic agents and is associated with an extremely poor prognosis. 19 This risk is drastically increased in patients who are children at the time of BMT. 20 The need for a well-coordinated multidisciplinary care system for BMT survivors (of all ages) has been previously discussed in the literature. 3 However, childhood BMT survivors (like Asha and Andrew) require even more specific care. In this review, we highlight the unique needs of childhood BMT survivors and identify some proposed models of care.
Psychological health
Although there is a paucity of literature addressing the prevalence of major depressive disorder, generalized anxiety disorder and PTSD among the specific population of childhood BMT survivors, one study found that 80% of childhood BMT survivors show moderate PTSD symptoms in the first 3 months post transplant. 15 The term 'Damocles syndrome' is cancer survivors' frequent experience of anxiety related to a fear of relapse, 21 experienced bỹ 89% of childhood cancer survivors, 22 including BMT survivors. Survivors of childhood cancer (especially BMT survivors) are also at heightened risk for anxiety, depression and antisocial behaviors. 23 Childhood survivors are 80% more likely than siblings to report clinical mental health impairment and twice as likely to report clinical levels of emotional distress. 24 A significant portion of BMT survivors are diagnosed with anxiety and depression specifically related to sexual dysfunction and/or impoverished self-image or social adjustment. 25, 26 In a study on survivors of leukemia, 31% of physically healthy BMT survivors experienced psychological distress in magnitudes indicative of psychiatric disorders. 27 Childhood BMT survivors demonstrate decreased quality of life and increased rates of behavioral issues. 28, 29 In the months following transplantation, 40% of children experience significant increases in anxiety, depression and aggression, and 35% 1 year later. 29, 30 Childhood BMT survivors also experience declines in social competence and self-concept. 31 Their peers describe them as 'less athletic, less likely to be chosen as a best friend, and less attractive'. 32 Neurocognitive effects Some previous studies have reported normal neurodevelopment among members of this population, 33 but there are no multicenter prospective studies on this topic. One study concluded that, on average, a patient's intelligence quotient dropped six points between baseline presentation and 1-year follow-up. 34 Pediatric BMT survivors often have fine motor deficits, cognitive problems, poor long-term memories and diminished learning abilities. [35] [36] [37] The largest longitudinal study on this topic reported poorer neurocognitive outcome in patients receiving TBI, unrelated donor transplants or GVHD. 38 In another study, only those who received TBI conditioning were unable to recover from this decline in subsequent years. 39 Other studies yielded agedependent results. [40] [41] [42] The reasons for these discrepancies are unknown.
The aforementioned sequelae negatively impact social functioning, including school attendance and employment. 42 A cancer survivor's self-image is often dependent on his or her career. 43 Compared to 2% of their healthy peers, 19% of pediatric BMT survivors identify employment as their 'main concern in life'. 44 Adult survivors of childhood cancer may be twice as likely as their peers to be unemployed. 45 Employment is difficult for survivors of childhood BMT because of its lasting repercussions, but it is also likely that a history of cancer and/or BMT leads to more job rejection and prejudice in the workforce.
Endocrine health Long-term consequences of childhood BMT on endocrine health include effects on thyroid functioning, bone health and sexual health and fertility. Potential problems in children and adolescents include poor growth, hypothyroidism, thyroid tumors and delayed or absent puberty. 46 Changes to fertility include gonadal failure and infertility, making lifelong impacts on survivors.
Thyroid dysfunction may manifest in childhood BMT survivors as subclinical compensated hypothyroidism, overt hypothyroidism, autoimmune thyroid disease or less common hyperthyroidism or thyroiditis. [47] [48] [49] These are linked to busulfan conditioning. 50 Pediatric BMT survivors have decreased bone mineral density and are at higher risk of fracture, osteonecrosis and osteoporosis (particularly females). [50] [51] [52] [53] [54] Avascular necrosis of bone occurs in more than 10% of BMT survivors. 54 Endocrine arrest of bone development refers to the decreased growth in childhood BMT survivors due to BMT conditioning and GVHD treatment. 55 Growth deficiency is more severe in survivors of BMT who received TBI or transplant before the age of 10 years. 56 Endocrine arrest of growth results in abnormally short stature and early fusion of growth plates preventing further growth.
11
Sexual health and fertility are often compromised during childhood BMT. It has been found that 53% of female childhood BMT survivors and 29% of male childhood BMT survivors are diagnosed with hypogonadism, 11 defined by low serum levels of estradiol in females or testosterone in males. 51 Another study on BMT survivors indicated that 83% of females and 69% of males later became sterile, including 91% of the BMT survivors treated later than age 13.
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In girls, high-dose chemotherapy and TBI often result in permanent ovarian failure. 58 As little as 15 Gy of radiation can cause fertility impairment in girls regardless of pubertal status. 59 Girls of any age are likely to develop ovarian failure, as the utilization of busulfan and cyclophosphamide conditioning continues to increase. 60 Uterine function is maintained in most female survivors of BMT who do not receive focal pelvic irradiation. These survivors may be able to carry a pregnancy that results from assisted fertility procedures.
In boys, changes to spermatogonia occur after 0.1 Gy of radiation, and permanent infertility occurs after doses of 2 Gy and above. 59 Pre-pubertal boys are at heightened risk of damage to the testes and often experience reduced testicular volume due to damage to the germinal epithelium. 61 Permanent infertility is a large possibility for male pediatric BMT recipients.
Infertility resources
In light of prominent sexual health and fertility issues, counseling of BMT patients prior to transplantation regarding impaired fertility and fertility conservation procedures should be considered. 57 Literature indicates that such discussions occur ~10% of the time at the start of gonadotoxic therapy for adults. 62 Among children diagnosed with cancer, these discussions occur even more rarely, as it is a great challenge for physicians to bring up fertility amidst a conversation of life-threatening diagnoses and therapies. 63, 64 In addition, the options for fertility preservation in pre-pubertal children are limited and not universally available.
Because of the quick and non-invasive nature of sperm collection, fertility counseling is much more likely to be offered to boys than to girls. 65 Sperm may be cryopreserved prior to BMT and used years later for artificial insemination, in vitro fertilization or in in vitro injection into the cytoplasm of an oocyte. 23 Traditional sperm donation requires that the patient has achieved pubertal development, but for pre-pubescent boys, preservation of testicular tissue is being increasingly utilized in many medical institutions in the Western world.
For women, cryopreserved embryos may currently be used in in vitro fertilization, though this process requires the selection of a male sperm donor. Preservation of ovarian tissue prior to BMT may be a good alternative. 23 Recent publications report pregnancy rates from this technology to be comparable to those of cryopreserved and fresh embryos. 66, 67 Unfortunately, ovarian cryopreservation is complicated by the amount of time it takes to retrieve ovarian tissue, which delays BMT conditioning. According to the American Society of Clinical Oncology, sperm and embryo cryopreservation should be considered standard practice, but all other types of fertility preservation methods are currently considered investigational. 68 Should patients miss the window of opportunity to preserve their fertility or choose not to do so, they should be made aware of other options for becoming parents as they transition to adulthood. Donor-assisted reproduction (labeled as third party reproduction by some) refers to the process of using a donated egg, sperm or embryo from a 'third party' to instill pregnancy in the birth mother or carrier through intrauterine insemination or in vitro fertilization. Donation can be anonymous, known or 'directed', meaning a friend or relative of the intended parents chooses to donate solely to that family. 69 Adoption, however, requires home study and examination of the family and is sometimes considered intrusive. 70 Unfortunately, due to the stigma associated with childhood disease, BMT survivors are more likely to experience discrimination during the adoption process. [69] [70] Issues in transition from pediatric to adult clinicians Transition is defined by the Society for Adolescent Medicine as the purposeful, planned movement of adolescents and young adults with chronic physical and medical conditions from child-centered to adult-oriented healthcare systems. 71 The success of such a transition heavily relies on deliberate guidance of caregivers and medical providers. Certain pediatric patients suffering from chronic illnesses may deteriorate rapidly at the time of transition of care, unless structured planned transition of care is implemented, as is seen in the case of patients with sickle cell disease. [72] [73] [74] Like sickle cell disease survivors, pediatric BMT survivors are a unique population with extensive preventative and supportive needs. When these needs are not met, not only does morbidity rise, but the risk for mortality is also heightened. Besides certain late effects that are known to be more prevalent in BMT survivors, the management of chronic GVHD in BMT survivors may be beyond the scope of a regular primary care physician.
The American Academy of Pediatrics, American Academy of Family Physicians and American College of Physicians-American Society of Internal Medicine have jointly issued a consensus statement delineating the critical first steps of ensuring successful transition to adult-oriented healthcare. 75 According to their recommendations, a step-by-step management is necessary for transition of care. A proposed modification tailored to the issues specific to BMT survivorship is given in Table 1 .
Preventative services A recent US Preventive Services Task Force article undermines the importance of establishing preventative guidelines specifically for young adults. 76 Their guidelines can be applied to all age groups but pertain to the general population. 77 The American Society for Blood and Marrow Transplantation and others have jointly recommended system/organ-based screening and preventive practices for BMT long-term survivors. 78 In general, we recommend that the US Preventive Services Task Force guidelines should be implemented (at minimum) and further consolidated with the preventative American Society for Blood and Marrow Transplantation guidelines.
Cost of care issues during BMT and transition The average costs of allogeneic BMT exceed US $200 000 for the first few months. 79, 80 BMT survivors who develop chronic GVHD Table 1 . Steps to ensure successful transition of pediatric and AYA BMT survivors into adult healthcare
Identification of a healthcare provider Ensure that all AYA BMT survivors have an identified healthcare professional (adult allied health professional or physician with expertise in oncology, hematology or BMT) who attends to the unique challenges of transition and assumes responsibility for current healthcare, care coordination and future healthcare planning.
Individualized care plans Prepare and maintain an up-to-date medical summary or an SCP that is accessible and ideally available in both paper and electronic format.
Healthcare transition plan Create a written healthcare transition plan for BMT survivors ideally before the age of 18 years, together with the BMT survivor and his family. Discuss this plan at length with the patient's parents to address how their roles may also change. At a minimum, this plan should include what services need to be provided, who will provide them and how they will be financed. This plan should be reviewed and updated annually and whenever there is a transfer of care.
Addressing healthcare coverage Ensure affordable, continuous health insurance coverage for all BMT survivors throughout adolescence and adulthood. This insurance should cover appropriate compensation for (1) healthcare transition planning for all AYA BMT survivors and (2) care coordination for essential preventative services to prevent late effects of both allogeneic and autologous BMT.
Communication
Continue to engage in communication with the patient's adult healthcare providers prior to and during the period of transition to ensure proper coordination of care.
Abbreviations: AYA = adolescent and young adult; BMT = blood and marrow transplantation; SCP = survivorship care plan.
Transition and long-term follow-up after pediatric BMTrequire multispecialty care and intense resources that often culminate in financial burden. 81 In addition, the indirect costs significantly affect the families of pediatric BMT survivors; recent data indicate that one in five pediatric BMT families report transplantation-related income losses 440%, and one in three pediatric BMT families report food, housing or energy insecurity after hematopoietic stem cell transplantation. 82 At the time of transition from pediatric care, adult providers are encouraged to address potential financial burdens and ensure continuity of insurance coverage for provision of necessary therapeutic and preventative care.
The Patient Protection and Affordable Care Act (ACA) was passed in March 2010, intending to increase access to healthcare while reducing its overall cost. Pediatric cancer survivors' coverage priorities and familiarity with the ACA were recently evaluated through the Childhood Cancer Survivor Study. 83 Only 21% of the cancer survivors and 19% of the survivor siblings believed the ACA would make it more likely that they would get quality coverage. Thus, considerable room for improvement in this knowledge gap is required, and education tools regarding the coverage included within ACA should be readily available to all BMT survivors at the time of transition.
Before the enactment of ACA, BMT survivors seeking new insurance coverage in the individual marketplace faced the possibility of being uninsured, and this was increased due to plans with prohibitively high premiums and pre-existing conditions that excluded costs related to BMT. The ACA has created a 'guaranteed renewal' requirement for all comers; anyone eligible for insurance cannot be turned away, including those with prior BMT. As of 2015, annual and lifetime dollar limits on total paid benefits are no longer allowed. Under the ACA, medical coverage will be available (through parental coverage) to young adults until the age of 26. 84 We anticipate that the full implementation of the ACA will be generally beneficial for pediatric BMT survivors. 85 
CONCLUSION
A patient transitioning from a pediatric to an adult BMT program encounters a unique situation, for the patient is not yet fully initiated into the 'adult mode.' Andrew and Asha are classic examples of the real-world issues that many pediatric and adolescent and young adult survivors of BMT face. A team approach to dealing with these issues can be very effective, but transitioning from a pediatric to an adult provider can be a challenge for all members of the care team. Very limited resources have been developed to help the care team prepare for and successfully manage this transition. This article provides a guide for the transition to adult long-term follow-up care team to manage late effects and chronic GVHD after transplantation in long-term survivors of childhood BMT. The goal of transition is to optimize health and assist youth in reaching their full potentialin both years lived and goals achieved.
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